Suicidality and Psychedelic-Assisted Therapy in Canada

If you or someone you know is in crisis, help is available right now.

• 9-8-8 Suicide Crisis Helpline (Canada) — call or text 9-8-8, 24/7, bilingual
• Talk Suicide Canada — 1-833-456-4566 (24/7); text 45645 (4 PM–midnight ET)
• Kids Help Phone (children, teens, young adults) — 1-800-668-6868; text CONNECT to 686868
• Quebec residents: 1-866-APPELLE (1-866-277-3553), 24/7
• In immediate danger: call 9-1-1 or go to your nearest emergency department

Psychedelic-assisted therapy is not a substitute for acute crisis care.

Suicidality is a clinical situation, not a diagnosis — it spans passive suicidal ideation ("I wish I weren't here"), active suicidal ideation with intent or plan, suicidal behavior including attempts, and the elevated lifetime risk seen across many psychiatric conditions. According to the Public Health Agency of Canada, suicide accounts for roughly 4,500 deaths each year in Canada and is a leading cause of death among Canadians aged 15–34. This article is a safety-first Canadian guide. It is not a "psychedelics fix suicide" article. The foundation of suicidality care is comprehensive psychiatric assessment, safety planning, removal of access to lethal means, treatment of the underlying disorder, and hospital-level care when appropriate. Within that foundation, certain interventional psychiatry options — particularly IV ketamine (off-label) and esketamine / Spravato (with regulator-recognized rapid-SI evidence) — have demonstrated rapid, partial reductions in suicidal ideation in carefully selected patients. This article walks through what that evidence does and does not show, and why ongoing safety planning never goes away.

Key takeaways

• Crisis comes first. 9-8-8 (Canada Suicide Crisis Helpline), Talk Suicide Canada 1-833-456-4566, Kids Help Phone 1-800-668-6868. In immediate danger, call 9-1-1 or go to an emergency department.
• Psychedelic-assisted therapy is not a replacement for acute suicide crisis care. Comprehensive psychiatric assessment, safety planning, means restriction, and hospitalization where appropriate are foundational and never replaced by a medication or a session.
• Rapid SI (suicidal ideation) reduction evidence — ketamine / esketamine: Wilkinson et al. 2017 individual-patient meta-analysis (PMID 28602100) showed IV ketamine produced rapid reductions in suicidal ideation across pooled RCT data; Canuso et al. 2018 (PMID 29656663) showed intranasal esketamine reduced SI in MDD patients at imminent suicide risk.
• Regulatory status: FDA approved Spravato + oral antidepressant for MDD with acute suicidal ideation or behavior in August 2020. Health Canada's Spravato label is for treatment-resistant depression; the acute SI indication is under label review and not a separate Health Canada-approved indication as of 2026.
• Effect sizes are partial. Not all patients respond. Suicidal ideation reduction does not equal suicide prevention. Ongoing safety planning is required.
• Different drugs, different SI populations: ketamine evidence sits in acute SI within depression; MDMA-AT (MAPP1/MAPP2) explicitly excluded patients with acute or imminent SI from PTSD trials; psilocybin RCTs (Bogenschutz, Mitchell, Goodwin) typically excluded acute SI; bipolar SI requires mood-stabilizer coordination.
• Black box / serious warnings on antidepressants for patients under 25 for suicidal ideation/behavior risk; this caution extends to esketamine considerations.
• Coverage pathways: VAC, WSIB (work-related), PSHCP, and private insurers may fund Spravato for label-aligned use; off-label ketamine is generally private-pay.

Defining suicidality

The Columbia Suicide Severity Rating Scale (C-SSRS) and similar frameworks describe suicidality on a continuum:

• Passive suicidal ideation — wish to be dead, no active intent
• Active suicidal ideation — thoughts of killing oneself, with or without method, intent, or plan
• Suicidal behavior — preparatory acts, aborted attempts, interrupted attempts, attempts
• Suicide death

Suicidality crosses diagnostic lines: it is elevated in major depressive disorder (especially treatment-resistant), bipolar disorder (depressive and mixed episodes), PTSD, borderline personality disorder, substance-use disorders, schizophrenia spectrum disorders, and others. It is also elevated in particular life situations — recent psychiatric hospitalization, recent loss, chronic pain, military / first-responder service, Indigenous youth populations, 2SLGBTQ+ youth.

What "first-line" looks like for suicidality — and why it isn't a psychedelic

Before any conversation about interventional or psychedelic-assisted options, the foundation of suicidality care is:

1. Comprehensive psychiatric assessment by a qualified clinician — DSM-5 differential, mood, psychosis, substance, trauma, medical contributors
2. Safety planning — Stanley-Brown Safety Plan model: warning signs, internal coping strategies, social contacts, professional contacts, means restriction
3. Means restriction — secure or remove firearms, lethal medications, and other access to lethal means (the strongest evidence-based suicide-prevention intervention at the population level)
4. Treatment of the underlying disorder — antidepressant / mood stabilizer / antipsychotic / trauma-focused therapy / DBT, as clinically appropriate
5. Crisis resource activation — 9-8-8, Talk Suicide Canada, mobile crisis teams, ER psychiatric assessment, mental health holds (provincial Mental Health Acts), inpatient stabilization
6. Continuity — follow-up after ER discharge, post-hospitalization follow-up, family involvement when appropriate

Specific evidence-based options for active suicidality include:

• Lithium for suicide-risk reduction in mood disorders (Cipriani 2013 meta-analysis)
• Clozapine for suicide-risk reduction in schizophrenia spectrum (InterSePT)
• DBT for chronically suicidal patients (Linehan)
• CBT for suicide prevention (CBT-SP, Brown)
• Caring contacts / postvention

Psychedelic-assisted therapy enters the picture, if at all, only as part of a comprehensive plan — never as a stand-alone substitute.

The evidence map — psychedelic-assisted therapy and suicidal ideation

Ketamine (off-label IV/IM/SL) — the strongest rapid-SI evidence base

• Wilkinson ST, Ballard ED, Bloch MH, et al. 2018 (often cited as Wilkinson 2017; Am J Psychiatry; PMID 28602100): individual-patient-data meta-analysis of 10 RCTs and 167 patients showed that a single dose of IV ketamine produced rapid reductions in suicidal ideation within 1 day, with effects measurable for up to a week, across mood-disorder populations.
• Murrough JW, Soleimani L, DeWilde KE, et al. 2015 (PMID 25624412): RCT of IV ketamine versus midazolam in patients with clinically significant suicidal ideation — significant SI reduction at 24 hours.
• Price RB, Iosifescu DV, Murrough JW, et al. 2014: replication evidence for rapid SI reduction with ketamine in TRD.
• Replication and translation: numerous additional RCTs and real-world cohorts have replicated rapid SI reduction signals; effect sizes are meaningful but partial, and durability beyond ~1 week typically requires continued treatment.

Esketamine (Spravato) — regulator-recognized acute-SI indication (FDA)

• Canuso CM, Singh JB, Fedgchin M, et al. 2018 (Am J Psychiatry; PMID 29656663): RCT of intranasal esketamine plus comprehensive standard care in patients with MDD at imminent risk of suicide showed rapid reduction in depressive symptoms. SI reduction signals were also present, with both groups reducing on the SI item — illustrating the partial-response and high-context-of-care reality.
• ASPIRE I and ASPIRE II (Fu, Ionescu, Canuso 2020 — published in J Clin Psychiatry and Lancet Psychiatry): two phase 3 RCTs of esketamine + standard of care versus placebo + standard of care in MDD with active suicidal ideation with intent.
• FDA approval: in August 2020, the FDA approved Spravato + oral antidepressant for the treatment of depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, based on ASPIRE.
• Health Canada: the Health Canada Spravato product monograph indication is for treatment-resistant depression. The acute SI / behavior indication has been the subject of ongoing label review and is not a separately Health Canada-approved indication as of 2026 — clinicians prescribing Spravato for an acutely suicidal MDD patient in Canada are working within or adjacent to the TRD label and applicable off-label / label-extension principles, with comprehensive safety wrap-around.

Psilocybin — acute SI typically excluded from RCTs

• Goodwin GM, Aaronson ST, Alvarez O, et al. 2022 NEJM (COMP001) (PMID 36322843) — acute / imminent suicide risk excluded from the trial.
• Carhart-Harris R, Giribaldi B, Watts R, et al. 2021 NEJM (PMID 33852780) — acute suicide risk excluded.
• Bogenschutz MP, et al. 2022 (psilocybin AUD) — excluded acute suicidality.
• Anand A, Mathew SJ, Sanacora G, et al. 2023 NEJM ELEKT-D (PMID 37224135) — TRD ketamine vs ECT; included some patients with SI within the broader TRD population, with safety monitoring, but did not specifically target acute imminent-risk patients.
• Implication: there is no robust RCT evidence base for psilocybin reducing acute suicidal ideation, and psilocybin under Health Canada's Special Access Program is generally not indicated for patients with current acute SI.

MDMA — acute SI excluded from MAPP trials

• Mitchell JM, Bogenschutz M, Lilienstein A, et al. 2021 (MAPP1, Nature Medicine) and Mitchell 2023 (MAPP2): phase 3 MDMA-assisted therapy for severe PTSD trials excluded patients with active / imminent suicide risk per protocol.
• Implication: MDMA-AT under Health Canada SAP is investigational for PTSD and is not appropriate for patients in acute suicidal crisis. SAP applications must include explicit screening and safety planning.

For more detail see Ketamine Therapy in Canada and Treatment-Resistant Depression and Psychedelic-Assisted Therapy.

Decision framework — when (and when not) to consider PAT alongside suicidality care

This framework is for stabilized patients in ongoing care, not for patients in acute crisis. Acute crisis = call 9-8-8 or go to an emergency department.

Canadian access pathways — and where they fit

Acute crisis pathways

• 9-8-8 Suicide Crisis Helpline (Canada) — 24/7 call/text
• Talk Suicide Canada — 1-833-456-4566 (24/7); text 45645 (4 PM–midnight ET)
• Kids Help Phone — 1-800-668-6868; text CONNECT to 686868
• Quebec Suicide Prevention Line — 1-866-APPELLE (1-866-277-3553)
• Hope for Wellness Helpline (Indigenous) — 1-855-242-3310; chat at hopeforwellness.ca
• Trans Lifeline (Canada) — 1-877-330-6366
• Provincial mobile crisis teams — many municipalities have integrated mental-health crisis response
• Emergency departments — psychiatric assessment; provincial Mental Health Act mechanisms (Form 1 / certification) where clinically indicated
• Inpatient psychiatric units — for stabilization

Spravato — when patient meets label-aligned criteria

• Health Canada label: TRD indication; ongoing label review for acute SI in MDD
• Insurance: PSHCP (Public Service Health Care Plan; Form M7520 prior auth); Manulife, Sun Life, Green Shield, Canada Life all have prior-auth pathways
• VAC for service-related conditions; WSIB for work-related
• Provider network: Janssen Journey-certified clinics
• Monitoring: in-clinic dosing with 2-hour post-dose observation; trained staff; full safety wrap-around

For more detail see PSHCP / Canada Life Spravato Coverage and Insurance Coverage for Psychedelic-Assisted Therapy in Canada.

Off-label ketamine (IV/IM/SL) — within an ongoing psychiatric plan

• Off-label legality is well-established under Canadian off-label prescribing principles; the medication is Health Canada-approved as an anaesthetic
• Out-of-pocket is the dominant pathway: typically $400–$1,500/session
• VAC / WSIB case-by-case for compensable / service-related conditions
• Public hospital exceptions: Edmonton Misericordia/Grey Nuns publicly funded outpatient psychiatric ketamine; Vancouver UBC Hospital VCH program
• Patients with current acute SI are typically managed in higher-intensity programs or inpatient before outpatient KAP

Psilocybin / MDMA — generally not for acute SI

• ATMA CENA will not support psilocybin or MDMA SAP applications where the primary clinical situation is current acute suicidality
• For end-of-life distress or PTSD without acute SI, SAP pathways may apply per the relevant condition-specific hubs

Special populations

Patients under 25

The black box warnings on antidepressants document increased risk of suicidal thoughts and behaviors in patients under 25 in the early phase of antidepressant treatment. This caution extends to esketamine considerations and to any new psychotropic introduction. Pediatric / youth psychiatric coordination is essential. Kids Help Phone is a critical resource: 1-800-668-6868, or text CONNECT to 686868.

Bipolar disorder

Suicidality risk in bipolar disorder is substantially elevated — particularly in depressive and mixed episodes. Mood stabilizer coordination is non-negotiable. Lithium has the strongest evidence base for suicide-risk reduction in bipolar disorder. See Bipolar Disorder and Psychedelic-Assisted Therapy.

PTSD

Suicidality is elevated in PTSD populations, particularly veterans and first responders. MDMA-AT MAPP1/MAPP2 trials excluded patients with active / imminent suicide risk per protocol. Patients in acute crisis are not candidates for MDMA-AT under Canadian SAP pathways. See PTSD and Psychedelic-Assisted Therapy and VAC Coverage.

Concurrent substance use

Active substance use complicates suicidality assessment and treatment. Means restriction in the substance-use context includes the substance itself. Coordination with addiction medicine is essential. See Concurrent Disorders and Psychedelic-Assisted Therapy.

Indigenous communities

The Hope for Wellness Helpline (1-855-242-3310) offers culturally informed crisis support in English, French, Cree, Ojibway, and Inuktitut. Trauma-informed, culturally safe psychiatric care is the foundation; psychedelic-assisted therapy considerations apply only within that broader frame.

What the evidence does NOT say

• Reducing suicidal ideation is not the same as preventing suicide. SI reduction in RCTs is typically measured on rating-scale items over hours-to-days; suicide is a low-base-rate outcome that requires much larger studies and different designs to address directly. No psychedelic-assisted therapy has been demonstrated to reduce suicide deaths at a population level.
• Effect sizes are partial. Not all patients respond. Many patients in trials remained suicidal despite measurable SI reduction.
• Durability is limited. Single-dose ketamine effects on SI typically wane within 1–2 weeks without continued treatment.
• Trial populations are not the same as walk-in clinic populations. Trials excluded many real-world complexities (active substance use, current acute SI in psilocybin/MDMA trials, severe personality disorder).
• Safety planning never goes away. A response on a depression rating scale does not retire the safety plan, the means restriction, the crisis numbers on the fridge, the family check-ins.
• Off-label ≠ unsupported. But off-label also doesn't mean a regulator has reviewed the specific use case for safety-effectiveness in the indication.

How ATMA CENA works with patients in this space

• Crisis triage first. If a patient discloses acute suicidal ideation during intake, ATMA CENA's clinical team will route to crisis resources (9-8-8, ER, treating psychiatrist) before any PAT discussion.
• Coordination with treating psychiatrist. ATMA CENA will not provide PAT to a patient with a recent suicidality history without an established psychiatric care relationship and a written safety plan.
• Coordinated care. Your treating psychiatrist, family physician, or psychotherapist remains primary; ATMA CENA layers on top.
• Honest framing. ATMA CENA does not market PAT as a suicide-prevention intervention. We discuss partial response, ongoing safety planning, and the limits of the evidence.
• No psilocybin / MDMA for acute SI. ATMA CENA will not support SAP applications where the primary clinical situation is current acute suicidality.

Frequently asked questions

I'm thinking about suicide right now. What should I do? Please call or text 9-8-8 (Canada Suicide Crisis Helpline), or call 1-833-456-4566 (Talk Suicide Canada). If you're in immediate danger, call 9-1-1 or go to your nearest emergency department. Psychedelic-assisted therapy is not a crisis intervention.

Does ketamine "treat" suicidal thoughts? Ketamine has demonstrated rapid, partial reductions in suicidal ideation in RCTs (Wilkinson 2017 meta-analysis, Murrough 2015). It does not cure suicidality, does not prevent suicide attempts in all patients, and does not replace comprehensive psychiatric care. Effects typically wane within 1–2 weeks without continued treatment.

Is Spravato approved in Canada for suicidal ideation? The Health Canada Spravato indication is for treatment-resistant depression. The FDA approved Spravato + oral antidepressant for MDD with acute suicidal ideation or behavior in August 2020 based on ASPIRE I/II. The Health Canada label review for that indication has been ongoing; as of 2026 it is not a separately Health Canada-approved indication.

Can I do psilocybin therapy if I have suicidal thoughts? Generally no — at least not for current acute suicidality. Psilocybin RCTs (Goodwin 2022, Carhart-Harris 2021) excluded patients with acute / imminent suicide risk. Health Canada SAP applications for psilocybin in patients with active SI face significant clinical resistance.

Can I do MDMA-AT if I have suicidal thoughts? MAPP1 and MAPP2 (Mitchell 2021, 2023) excluded patients with active / imminent suicide risk per protocol. MDMA-AT under Canadian SAP is not appropriate for patients in acute suicidal crisis.

What about my teenager? Pediatric and youth suicidality requires specialized assessment. Kids Help Phone is open 24/7: 1-800-668-6868, or text CONNECT to 686868. Black-box warnings on antidepressants apply to patients under 25. ATMA CENA does not provide PAT to patients under the age of majority.

Will my insurance cover ketamine or Spravato for suicidality? Spravato has a structured prior-authorization pathway with most major insurers (PSHCP, Manulife, Sun Life, Green Shield, Canada Life) for the TRD indication. Off-label ketamine is generally private-pay. VAC and WSIB may fund within service-related or work-related claims. See Insurance Coverage Hub.

Can I share my suicidal thoughts honestly with the clinical team? Yes — please do. Honest disclosure protects you. ATMA CENA's clinical team is non-judgmental and will use that information to make appropriate clinical decisions, including coordinating with your treating psychiatrist and crisis resources. We will not deny care reflexively for honest disclosure.

What if my treating psychiatrist hasn't heard of this? ATMA CENA's clinical team can communicate with your treating psychiatrist directly with your consent — sharing the relevant evidence base, regulatory status, and proposed care plan.

What's the role of safety planning? Foundational. A Stanley-Brown Safety Plan — warning signs, internal coping strategies, social contacts, professional contacts, means restriction, crisis numbers — is the baseline of suicidality care, before, during, and after any PAT intervention.

Sources

1. Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, et al. (2018). The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry, 175(2):150-158. PMID: 28602100.
2. Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, et al. (2018). Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatry, 175(7):620-630. PMID: 29656663.
3. Murrough JW, Soleimani L, DeWilde KE, Collins KA, Lapidus KA, Iacoviello BM, et al. (2015). Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med, 45(16):3571-80. PMID: 25624412.
4. Fu DJ, Ionescu DF, Li X, Lane R, Lim P, Sanacora G, et al. (2020). Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). J Clin Psychiatry, 81(3):19m13191.
5. Ionescu DF, Fu DJ, Qiu X, Lane R, Lim P, Kasper S, et al. (2021). Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). Int J Neuropsychopharmacol, 24(1):22-31.
6. Anand A, Mathew SJ, Sanacora G, et al. (2023). Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression (ELEKT-D). New England Journal of Medicine, 388(25):2315-2325. PMID: 37224135.
7. Cipriani A, Hawton K, Stockton S, Geddes JR. (2013). Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ, 346:f3646. PMID: 23814104.
8. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
9. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
10. Stanley B, Brown GK. (2012). Safety planning intervention: a brief intervention to mitigate suicide risk. Cogn Behav Pract, 19(2):256-264.
11. FDA — Spravato (esketamine) Supplemental NDA approval letter (MDD with acute suicidal ideation or behavior, August 2020): https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211243Orig1s003ltr.pdf
12. Health Canada — Spravato Product Monograph: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
13. Public Health Agency of Canada — Suicide in Canada surveillance: https://www.canada.ca/en/public-health/services/publications/healthy-living/suicide-canada-key-statistics-infographic.html
14. LivingWorks ASIST (Applied Suicide Intervention Skills Training) — suicide intervention training framework: https://www.livingworks.net/asist
15. 9-8-8 Suicide Crisis Helpline (Canada): https://988.ca/

Related articles

• Treatment-Resistant Depression and Psychedelic-Assisted Therapy
• Bipolar Disorder and Psychedelic-Assisted Therapy
• PTSD and Psychedelic-Assisted Therapy
• Concurrent Disorders and Psychedelic-Assisted Therapy
• PSHCP / Canada Life Spravato Coverage
• Ketamine Therapy in Canada
• Insurance Coverage for Psychedelic-Assisted Therapy in Canada

Last updated: 2026-05-06